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Abstract
Background: The leaves of Strobilanthes crispus (S. crispus) which is native to the regions of Madagascar to the
Malay Archipelago, are used in folk medicine for their antidiabetic, diuretic, anticancer and blood pressure lowering
properties. Crude extracts of this plant have been found to be cytotoxic to human cancer cell lines and protective
against chemically-induced hepatocarcinogenesis in rats. In this study, the cytotoxicity of various sub-fractions of
dichloromethane extract isolated from the leaves of S. crispus was determined and the anticancer activity of one of
the bioactive sub-fractions, SC/D-F9, was further analysed in breast and prostate cancer cell lines.
Methods: The dichloromethane extract of S. crispus was chromatographed on silica gel by flash column
chromatography. The ability of the various sub-fractions obtained to induce cell death of MCF-7, MDA-MB-231,
PC-3 and DU-145 cell lines was determined using the LDH assay. The dose-response effect and the EC50 values of
the active sub-fraction, SC/D-F9, were determined. Apoptosis was detected using Annexin V antibody and
propidium iodide staining and analysed by fluorescence microscopy and flow cytometry, while caspase 3/7 activity
was detected using FLICA caspase inhibitor and analysed by fluorescence microscopy.
Results: Selected sub-fractions of the dichloromethane extract induced death of MCF-7, MDA-MB-231, PC-3 and
DU-145 cells. The sub-fraction SC/D-F9, consistently killed breast and prostate cancer cell lines with low EC50 values
but is non-cytotoxic to the normal breast epithelial cell line, MCF-10A. SC/D-F9 displayed relatively higher
cytotoxicity compared to tamoxifen, paclitaxel, docetaxel and doxorubicin. Cell death induced by SC/D-F9 occurred
via apoptosis with the involvement of caspase 3 and/or 7.
Conclusions: A dichloromethane sub-fraction of S. crispus displayed potent anticancer activities in vitro that can be
further exploited for the development of a potential therapeutic anticancer agent.
Background
Cancer is a major public health problem worldwide with
millions of new cancer patients diagnosed each year and
many deaths resulting from this disease. Chemotherapy
remains the principal mode of treatment for various
cancers. Tamoxifen, a non-steroidal anti-estrogen drug,
is used in the treatment of estrogen receptor (ER)-
positive breast cancer patients and as chemoprevention
in high risk women [1] but is not effective against ER-
negative breast tumours [2]. The anthracycline doxoru-
bicin is frequently used as a chemotherapeutic agent
against metastatic breast cancers [3]. Plant alkaloids like
docetaxel and paclitaxel are considered highly active
chemotherapeutic agents in various cancers including
those of the breast and prostate [4,5]. However, develop-
ment of resistance to chemotherapeutic drugs impedes
effective killing of the cancer cells, resulting in tumour
recurrence. In addition, patients usually suffer from
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any medium, provided the original work is properly cited.serious side-effects such as cardiac and other toxicities
[6-8].
Natural products have historically and continually
been investigated for promising new leads in pharma-
ceutical development [9,10]. Strobilanthes crispus (L.)
Blume (S. crispus) is distributed throughout the regions
of Madagascar to the Malay Archipelago [11] (Figure 1).
Traditionally known as ‘pecah beling’ or ‘pecah kaca’,
the leaves of this plant are boiled with water and used
in folk medicine for their antidiabetic, diuretic, antican-
cer and blood pressure lowering properties [12,13].
However, only a few scientific studies have been con-
ducted to evaluate the reputed efficacy of the plant.
S. crispus has high mineral content and contains poly-
phenols, catechins, alkaloids, caffeine, tannins and vita-
mins [14] and bioactive components such as stigmasterol
and b-sitosterol [15]. The water extract of this plant was
reported to contain compounds with very high binding
affinity to protein molecules, hence, inhibiting the prolif-
eration of retroviruses [16]. Pharmacological studies have
further shown the ability of S. crispus in preventing che-
mically-induced hepatocarcinogenesis in rats [17-19].
Administration of S. crispus extract also reduced the
severity of hepatic necrosis in rats with
diethylnitrosamine- and acetylaminofluorene-induced
hepatocellular carcinoma and this was suggested to be
due to the inhibition of enzymes involved in metabolic
activation of the carcinogens [20]. In vitro studies
demonstrated that crude methanol (MeOH) extract of
S. crispus was cytotoxic against HepG2 (liver), Caco-2
(colon) and MDA-MB-231 (breast) cancer cell lines while
the chloroform extract was found to be cytotoxic to
HepG2 and Caco-2 cells only [15]. These authors also
reported that stigmasterol and b-sitosterol isolated from
S. crispus leaves were cytotoxic to Caco-2, HepG-2,
MCF-7 as well as MDA-MB-231 (stigmasterol only) cells.
The essential oils of this plant, however, did not display
any cytotoxic activity in these cell lines, despite their high
antioxidant content [21].
I nt h ec u r r e n ts t u d y ,t h ec y t o t o x i c i t yo fv a r i o u ss u b -
fractions of the dichloromethane (DCM) extract of
S. crispus was determined and the apoptotic activity of
one of the sub-fractions with high cytotoxic potential
was further analysed in breast and prostate cancer cell
lines. Various sub-fractions of the DCM extract of S.
crispus were able to selectively induce cell death of
breast and prostate cancer cell lines. One of the bio-
active sub-fractions, SC/D-F9, was found to be relatively
Figure 1 Strobilanthes crispus. Strobilanthes crispus (Acanthaceae) Blume, also known by its vernacular name of ‘pecah beling’ or ‘pecah kaca’,i s
a flowering shrub distributed throughout the regions of Madagascar to the Malay Archipelago [11]. The plant can either be found wild in
scrublands and river banks or cultivated. A mature plant may grow up to a height of 2 m. The stems are grayish in colour, the branches are dark
green, the top surface of the leaves are darker green compared to the surface below, oblong to lanceolate in shape with the sides slightly
crenated. Both surfaces of the leaves are very scabrid. The corollas are pubescent and yellowish while the calyx segments are covered with
patent long and short hairs [12,35].
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Page 2 of 14more potent than doxorubicin, paclitaxel, docetaxel and
tamoxifen (low dose) in vitro, and induced cancer cell
death via apoptosis.
Methods
Plant material
S. crispus (L.) Blume (Acanthaceae) plants were col-
lected from Tasek Gelugur, Pulau Pinang, Malaysia. The
plant was authenticated and a voucher specimen of the
plant (no. 11046) was deposited at the herbarium of the
School of Biological Sciences, Universiti Sains Malaysia.
Extraction procedures
Fresh leaves of S. crispus (6 kg) was cut with a mill grin-
der into fine pieces and macerated with hexane (20 L)
for three days at room temperature (ca. 25-27°C) (Figure
2). After removing the hexane extract, the residue was
then macerated with DCM (20 L) for three days. The
extracts were filtered by gravity and the solvents were
evaporated under reduced pressure at < 35°C.
Fractionation of the active plant extract
The DCM extract above was tested and found to be
cytotoxic (data not shown) and thus warranted further
investigation. The DCM extract (approximately 2 g) was
chromatographed on a glass column (50 mm i.d.)
packed with silica gel 60, 0.040-0.063 mm (Merck,
Darmstadt, Germany) (200 g). Gradient step elution was
carried out using a combination of hexane, DCM and
MeOH with an initial ratio of hexane-DCM-MeOH,
9:1:0 (v/v/v), followed by 4:1:0, 3:2:0, 2:3:0, 1:4:0, 0:1:0,
0:95:5, 0:9:1, 0:4:1, 0:3:2 and 0:2:3 (v/v/v). The volume of
the solvent combination used in each gradient step was
400 ml. Nitrogen gas pressure was applied onto the col-
umn at 1 bar to increase the flow of the mobile phase.
Eluents were collected in portions of 40 ml. Finally the
column was flushed with MeOH.
A small sample of each eluent was evaluated using
thin layer chromatographya n dt h o s ee l u e n t sw h i c h
showed similar chemical composition were combined
and concentrated under vacuum to yield a total of 15
DCM sub-fractions designated as SC/D-F1, SC/D-F2,
SC/D-F3, SC/D-F4, ..., SC/D-F15 (Figure 2).
Cell culture
A concentrated stock solution of S. crispus extracts and
fractions was prepared in dimethyl sulphoxide (DMSO)
and stored at -20°C until required. Prior to analysis, the
samples were diluted in an appropriate growth culture
medium with the final concentration of DMSO in cul-
ture of ≤ 0.1%.
Human breast (MCF-7 and MDA-MB-231) and pros-
tate (PC-3 and DU-145) cancer cell lines and normal
breast epithelial cell line (MCF-10A) were obtained
Figure 2 Flow chart of extraction procedure for S. crispus. S. crispus leaves were macerated with hexane followed by DCM and fractionated
by column chromatography using different combinations of hexane, DCM and MeOH into 15 sub-fractions of differing polarity.
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(Rockville, USA). MCF-7 and DU-145 cells were cul-
tured in RPMI-1640 medium, MDA-MB-231 cells in
Dulbecco’s modified Eagle’s medium (DMEM), PC-3
cells in Ham F12K medium and MCF-10A in DMEM:
Ham F12K (1:1) medium, all supplemented with 100
units/ml penicillin, 100 μg/ml streptomycin (Gibco BRL,
USA) and 10% fetal bovine serum (Hyclone, USA) and
maintained at 37°C in a humidified atmosphere of 5%
CO2 in air.
Cytotoxicity Assay
The cytotoxicity of S. crispus DCM sub-fractions was
determined using the LDH Cytotoxicity Detection Kit
(Roche Diagnostics, Germany) which quantifies the
release of lactate dehydrogenase (LDH) from the cells
into the culture medium. The cells were seeded in 24-
well plates at a density of 1 × 10
5 (PC-3, DU-145 and
MCF-10A), 2 × 10
5 (MCF-7) or 1 × 10
6 cells/ml (MDA-
MB-231) and grown until about 70% confluence. The
medium was then replaced with fresh medium contain-
ing 2% fetal bovine serum prior to treatment with the
fractions of the extracts for up to 72 hr. The control
cells received not more than 0.1% DMSO which was
used as a solvent for the extract. Maximum LDH release
(high control) was determined by solubilising cells with
1% (w/v) Triton X-100 and spontaneous LDH release
(low control) was determined by incubating cells with
the medium alone. Cell-free supernatants from the cul-
tures were collected and transferred to 96-well plates for
measurement of LDH activity. A reduction reaction of
tetrazolium salts, INT, to a red formazan salt was used
as an indicator of LDH activity in the supernatant.
Absorbance was read at 490 nm and 620 nm reference
absorbance by using a microplate reader (Versamax,
USA). Results were expressed as % cytotoxicity [(experi-
mental value-low control/high control-low control) ×
100]. Effective concentration (EC50)v a l u e sw e r e
expressed as μg/ml concentration of the extract that
causes 50% cell growth inhibition.
Annexin V-FLUOS Assay
Apoptosis was determined using the Annexin-V FLUOS
Staining Kit (Roche, Germany) in combination with pro-
pidium iodide, according to the manufacturer’si n s t r u c -
tions. Briefly, cells were cultured in chamber slides or
T 2 5f l a s k sa tad e n s i t yo f5×1 0
5 cells/ml and allowed
to attach overnight, followed by treatment with the SC/
D-F9 or anticancer drugs for 24 or 48 hr. Cells were
then washed with phosphate-buffered saline (PBS) and
incubated with Annexin-V FLUOS labeling solution
(containing 2 μl Annexin-V-FLUOS labeling reagent and
2 μl propidium iodide solution in 100 μl incubation buf-
fer) for 10-15 min at room temperature. Analysis was
carried out by fluorescence microscopy (Nikon, USA)
and flow cytometry (FACS Calibur, Becton-Dickinson,
USA). A minimum of 10,000 events were collected for
analysis.
Determination of Caspase 3/7 Activity
Cells were cultured in chamber slides as above for detec-
tion of active caspase 3/7 by fluorescence microscopy
using the Carboxyfluorescein FLICA Apoptosis Detection
Kit (Immunochemistry Technologies, LLC), according to
the manufacturer’s instructions. Cells were labeled with
green fluorescent FAM-VAD-FMK and caspase-3/7
activity was analysed by fluorescence microscopy.
Determination of Total Phenolic Content
Total phenol estimation was determined according to a
previously described method [22]. A 0.2 N Folin-Ciocalteu
reagent (500 μl) was added to 1 ml aliquots of the extract
(1 mg/ml) and vigorously mixed by vortexing. The mix-
ture was then incubated at room temperature for 3 min.
Subsequently, 4 ml sodium carbonate solution (7.5% w/v)
was added and the mixture was incubated at room tem-
perature for 60 min. Finally, the absorbance was measured
at 760 nm using a spectrophotometer (Shimadzu, Japan)
and the measurement was compared to a standard curve
of gallic acid. The mean value (± SD) of triplicate analyses
is expressed as mg gallic acid equivalents per g plant mate-
rial (GAE/g).
Determination of Total Flavonoid Content
Total flavonoid content was determined according to
the method of Sakanaka et al. [23]. The extract (250 μl,
1 mg/ml) was mixed with distilled water (1.25 ml) and
sodium nitrite [75 μl, 5% (w/v)] and incubated at room
temperature for 6 min. Subsequently, aluminium chlor-
ide solution [150 μl, 10% (w/v)] was added and the mix-
ture was further incubated for 5 min before the addition
of sodium hydroxide (0.5 ml, 1 M). Thereafter, distilled
water (275 μl) was added and vortexed. Finally, the
absorbance was measured at 510 nm using a spectro-
photometer and the measurement was compared to a
standard curve of catechin. The value (mean of triplicate
analyses) is expressed as mg catechin equivalents per g
plant material (CE/g).
Statistical Analysis
Data are presented as mean ± standard deviation (SD)
of three independent experiments and statistical signifi-
cance was determined using Independent Student T test
and the SPSS software (SPSS Science Inc.)
Results and Discussion
Chromatographic separation of DCM extract of S. cris-
pus produced a total of 15 sub-fractions. The cytotoxic
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on the measurement of cytoplasmic LDH enzyme
released into the cell culture medium upon damage of
the plasma membrane. LDH is a widely used marker in
cytotoxicity studies and is a more sensitive indicator of
cellular damage compared to the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [24].
Various sub-fractions of DCM extract of S. crispus were
found to be highly cytotoxic to the cancer cells while
others caused marginal cell death or not at all effective.
SC/D-F1 totally killed MDA-MB-231 cells at 48 h but
was non-cytotoxic to MCF-7 cells up to 72 hr post-
treatment (Figure 3). This sub-fraction was also effective
in killing PC-3 and DU-145 cells. SC/D-F3 on the other
hand, acted specifically on MCF-7 cells only, causing
100% cell death at 72 hr post-treatment but was not at
all effective against the MDA-MB-231 cells. Interest-
ingly, SC/D-F8, SC/D-F9 and SC/D-F10 were found to
be consistently highly cytotoxic to all four human breast
and prostate cancer cell lines tested, at 24 hr post-treat-
ment. SC/D-F13, SC/D-F14 and SC/D-F15 induced
maximum cell death of MCF-7 breast cancer cells
within 48 hr but were less potent towards the MDA-
MB-231 and the prostate cancer cells.
MCF-7 cell line is estrogen receptor (ER)-dependent
and carries the wild type tumour suppressor p53 gene,
while the highly aggressive MDA-MB-231 is an ER-inde-
pendent breast cancer cell line, and is a p53 mutant
[25,26]. PC-3 and DU-145 are androgen-insensitive
prostate cancer cells [27]. PC-3 is of an aggressive phe-
notype while DU-145 cells have a more moderate meta-
static potential [28,29]. In addition, both prostate cancer
cells do not express normal p53 gene. The selective
cytotoxic effects of the different DCM sub-fractions
observed against the various cancer cell lines tested may
be hormone-dependent or -independent, p53-related or
influenced by other properties of the cancer cell lines,
although these characteristics are yet to be determined.
One of the most cytotoxic sub-fractions of the DCM
extract of S. crispus,S C / D - F 9 ,w a sf u r t h e ra n a l y s e dt o
establish its EC50 values in the breast and prostate can-
cer cell lines. Figure 4 shows the dose-response curves
and the EC50 values for SC/D-F9 in these cells. SC/D-F9
potently inhibited the growth of MCF-7 and MDA-MB-
231 breast cancer cells as well as the prostate cancer
cells, PC-3 and DU-145, in a time- and dose-related
fashion, with low constant EC50 values of 8.5, 10.0, 7.4
and 7.2 μg/ml, respectively.
We further demonstrate that SC/D-F9 is much more
effective in inducing cell death compared to some of the
commonly used chemotherapeutic agents, tamoxifen,
doxorubicin, paclitaxel and docetaxel, in ER-dependent
and ER-independent breast cancer cells as well as the
androgen-insensitive prostate cancer cells. At the
constant EC50 value of 8.5 μg/ml, SC/D-F9 caused an
average of 44% and 57% MCF-7 cell death in 24 and
48 hr, respectively (Figure 5). Except for the high con-
centration tamoxifen (15 μM), 5 μM tamoxifen, 10 and
1 0 0n Mp a c l i t a x e la sw e l la s5 0a n d2 5 0n Md o x o r u b i -
cin either did not induce significant death of these can-
cer cells or displayed much less cytotoxic activity than
SC/D-F9, within 48 hr. The MDA-MB-231 cells are
more sensitive to SC/D-F9 treatment (10.0 μg/ml) which
resulted in 80% cell death within 48 hr, similar to the
effect of 15 μM tamoxifen (Figure 5). However, pacli-
taxel (100 nM) and doxorubicin (250 nM) only killed
about 24% and 9% of these ER-independent breast can-
cer cells. Therefore, we can infer that the cancer cell
killing activity of SC/D-F9 is independent of whether
the cells express ER or not, indicating that SC/D-F9 has
the potential advantage over ER-dependent drugs such
as tamoxifen.
At the constant EC50 dose of 7.4 μg/ml, SC/D-F9
effectively killed 90% of PC-3 cells while docetaxel
(5 and 20 nM), paclitaxel (5 and 50 nM) and doxorubi-
cin (10 and 100 nM) killed less than 30% of these cells
(Figure 6). More than 50% of DU-145 cells were killed
by SC/D-F9 (7.2 μg/ml) within 48 hr. In comparison,
docetaxel (20 nM) caused about 40% cell death while
paclitaxel and doxorubicin resulted in less than 10% cell
death. These further indicate that SC/D-F9 is not speci-
fically selective for breast cancer cells only and that its
mechanism of action may not be hormone-dependent.
Importantly, we found that SC/D-F9 is non-cytotoxic
to the normal breast epithelial cell line, MCF10A, even
at twice the constant EC50 d o s ef o ru pt o7 2h rw h i l e
some of the chemotherapeutic agents (especially 15 μM
tamoxifen) are found to significantly kill these normal
cells (Figure 7). Similarly, crude extracts and essential
oils of S. crispus leaves were reported to be non-toxic to
the normal Chang liver cell line [15,21].
Disruption in the balance between the cell-generating
process of mitosis and apoptotic cell death can lead to
the development of cancer. Blocking cell proliferation
and inducing apoptosis are thus considered as important
properties of chemopreventive and chemotherapeutic
agents [30]. Hence, further analysis was carried out on
SC/D-F9 to determine its ability to induce apoptosis.
Hallmarks of apoptosis include cell shrinkage, chromatin
condensation, nuclear fragmentation and exposure of
phosphatidylserine on the surface of cells at the early
stages [reviewed in [31]]. Apoptosis in the current study
was confirmed by staining cells with the fluorescence-
conjugated Annexin-V antibody that binds to phosphati-
dylserine, and combined with propidium iodide that
stains the DNA of cells in their very late stages of apop-
tosis or of those undergoing necrosis due to compro-
mised plasma membrane permeability. Fluorescence
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Page 5 of 14Figure 3 Cytotoxicity of dichloromethane sub-fractions of S. crispus on breast and prostate cancer cell lines. MCF-7 (A), MDA-MB-231 (B),
DU-145 (C) and PC-3 (D) cells were treated with various dichloromethane sub-fractions of S. crispus (100 μg/ml) for 24, 48 and 72 hr and
cytotoxicity was measured using the LDH release assay. Each value represents the mean of triplicate determinations.
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Page 6 of 14Figure 4 Dose-response effect and EC50 values of SC/D-F9 on breast and prostate cancer cell lines. Dose- and time-dependent effect of a
bioactive sub-fraction of dichloromethane extract of S. crispus, SC/D-F9 on MCF-7 (A), MDA-MB-231 (B), DU-145 (C) and PC-3 (D) cells using the
LDH assay (prepared in triplicates). The EC50 values were plotted against each time point for the determination of the respective constant EC50
values (E to H).
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Page 7 of 14Figure 5 Comparison of the cytotoxic effect of SC/D-F9 with tamoxifen, paclitaxel and doxorubicin in breast cancer cells. MCF-7 and
MDA-MB-231 cells were treated with 8.5 and 10.0 μg/ml SC/D-F9, respectively, 5 and 15 μM tamoxifen (T5, T15), 10 and 100 nM paclitaxel (P10,
P100) and 50 and 250 nM doxorubicin (Dx50, Dx250), for 24 and 48 hr. The control cultures contained the solvent (0.1% DMSO). The
percentages of cell death induced were determined using the LDH release assay and each data represents the mean ± SD from three
independent experiments. Statistical analysis was determined using the Student T test with * p < 0.05; ** p < 0.01; *** p < 0.001, compared to
control.
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Page 8 of 14Figure 6 Comparison of the cytotoxic effect of SC/D-F9 with docetaxel, doxorubicin and paclitaxel on prostate cancer cells.D U - 1 4 5
and PC-3 cells were treated with 7.2 and 7.4 μg/ml SC/D-F9, respectively, 5 and 20 nM docetaxel (Dc5, Dc20), 10 and 100 nM doxorubicin
(Dx10, Dx100) and 5 and 50 nM paclitaxel (P5, P50) and, for 24 and 48 hr. The control cultures contained 0.1% DMSO. The percentages of cell
death induced were determined using the LDH release assay and each data represents the mean ± SD from three independent experiments.
Statistical analysis was determined using the Student T test with * p < 0.05; ** p < 0.01; *** p < 0.001, compared to control.
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crispus induced cell death of all four breast and prostate
cancer cells by apoptosis as depicted by strong reaction
of these cells with the Annexin V antibody (green),
compared to control (DMSO-treated) cells (Figure 8).
Significant apoptosis occurs in tamoxifen-treated MCF-7
and MDA-MB-231 cells although much less staining of
paclitaxel-treated PC-3 and DU-145 cells is observed.
Some propidium iodide staining (red) is also noted in
the cells treated with SC/D-F9, tamoxifen and paclitaxel,
indicating very late stage apoptosis or necrosis. Figure 9
shows specific percentage distributions of these cells as
obtained by flow cytometry. SC/D-F9 effectively caused
both ER-positive and ER-negative breast cancer cells to
Figure 7 The effect of SC/D-F9, tamoxifen, paclitaxel, doxorubicin and docetaxel on MCF-10A cells. MCF-10A cells were treated with SC/
D-F9 (8.5 and 17.0 μg/ml), 5 and 15 μM tamoxifen (T5, T15), 10 and 100 nM paclitaxel (P10, P100), 50 and 250 nM doxorubicin (Dx5, Dx250) as
well as 10 and 100 nM docetaxel (Dc10, Dc100) for 24, 48 and 72 hr. The control cultures contained 0.1% DMSO. Each value represent the mean
± SD from three independent experiments. Statistical analysis was determined using the Student T test with * p < 0.05; ** p < 0.01; *** p <
0.001, compared to control.
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induce more apoptosis of the androgen-insensitive pros-
tate cancer cells compared to paclitaxel within 48 hr. To
further confirm the apoptotic activity of SC/D-F9, the
ability of this sub-fraction to activate the effector cas-
pase 3 or 7 was determined using a potent fluorescent-
labeled caspase inhibitor that covalently binds to active
caspase within the cells. In all four breast and prostate
cancer cells, it can be inferred that apoptosis involves
caspase signaling since the caspase 3 and/or 7 was
found to be activated by SC/D-F9 although to a lesser
extent in the prostate cancer cells compared to breast
cancer cells (Figure 10).
Androgens regulate prostate cancer cell growth and
differentiation. Current medical therapy for prostate
cancer patients includes anti-androgens which inhibit
Figure 8 Apoptosis of breast and prostate cancer cells by SC/D-F9, tamoxifen and paclitaxel. MCF-7 (A-C) and MDA-MB-231 (D-F) cells
were treated with DMSO (0.1%), SC/D-F9 (8.5 or 10.0 μg/ml, repectively), and tamoxifen (15 μM) for 24 hr while the PC-3 (G-I) and DU-145 (J-L)
cells were treated with DMSO (0.1%), SC/D-F9 (7.4 and 7.2 μg/ml, respectively) and paclitaxel (50 nM) for 48 hr. The cells were stained with
annexin V-FITC antibody (green staining) and propidium iodide (red staining) and observed using a fluorescence microscope (20× magnification).
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Page 11 of 14Figure 9 Percentage distribution of SC/D-F9-induced apoptotic and necrotic breast and prostate cancer cells. MCF-7 and MDA-MB-231
cells were treated with DMSO (0.1%), SC/D-F9 (8.5 or 10.0 μg/ml, repectively), and tamoxifen (15 μM) for 24 hr while the PC-3 and DU-145 cells
were treated with DMSO (0.1%), SC/D-F9 (7.4 and 7.2 μg/ml, respectively) and paclitaxel (50 nM) for 48 hr. The cells were stained with annexin V-
FITC antibody and propidium iodide and analysed by flow cytometry.
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Page 12 of 14the binding of androgens to the androgen receptor, as
well as gonadotrophin-releasing hormone (GnRH) ana-
logues which downregulate GnRH receptors leading to
the inhibition of androgen production [32]. This would
therefore lead to apoptosis of prostate cancer cells.
However, treatment for hormone-resistant prostate can-
cer is limited and addition of anti-androgens may pro-
duce only a transient biochemical response [32]. DU-
145 and PC-3 cells are both androgen receptor-positive
but androgen non-responsive [27] and hence SC/D-F9
may provide a potential complementary therapeutic
agent for hormone resistant prostate cancer.
Analysis of SC/D-F9 showed that it has a total phenolic
content of 29.0 ± 0.867 mg/g of gallic acid and a total fla-
vonoid content of 59.0 ± 0.333 mg/g of catechin. These
amounts are higher than those reported on some other
plant extracts [33,34] and these may contribute to the
anticancer effects of SC/D-F9 observed in this study,
although this has yet to be confirmed. In addition, it has
earlier been reported that S. crispus extract has high anti-
oxidant activity that may be attributed to the presence of
catechin as well other flavonoids [14]. Since SC/D-F9 is
shown to effectively induce apoptosis in androgen non-
responsive prostate cancer cells as well as ER-positive
and ER-negative breast cancer cells in the current study,
the potential of the S. crispus plant to be developed
further as a cancer therapeutic agent should be explored.
Apoptosis is a tightly regulated process controlled by var-
ious intracellular signaling molecules involved in differ-
ent pathways [31]. Work is currently underway to
identify the bioactive component(s) in SC/D-F9 to
further understand the mechanism of action of S. crispus.
Conclusions
A large number of novel anticancer drugs have been
discovered from natural products in the past and new
ones are continually being developed. These cytotoxic
natural products may be able to play a significant role
in treating selected cancers by working in concert with
conventional chemotherapeutic drugs thereby improving
their efficacy or reducing their toxicity. We have shown
that S. crispus has potent anticancer activities in vitro
and could therefore, potentially be a source for a phar-
macologically active product suitable for development as
a chemotherapeutic agent.
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